Cardiff Oncology, Inc.
General ticker "CRDF" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $176.7M (TTM average)
Cardiff Oncology, Inc. does not follow the US Stock Market performance with the rate: -10.9%.
Estimated limits based on current volatility of 3.5%: low 2.09$, high 2.24$
Factors to consider:
- Total employees count: 33 (+3.1%) as of 2024
- Top business risk factors: Regulatory and compliance, Economic downturns and volatility, Supply chain disruptions, Pandemic risks, Litigation risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.91$, 5.80$]
- 2025-12-31 to 2026-12-31 estimated range: [1.15$, 3.70$]
Financial Metrics affecting the CRDF estimates:
- Positive: with PPE of -4.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -18.50 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 6.74 > -0.66
- Negative: negative Net income
Short-term CRDF quotes
Long-term CRDF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.39MM | $0.49MM | $0.68MM |
| Operating Expenses | $40.29MM | $45.90MM | $49.33MM |
| Operating Income | $-39.90MM | $-45.41MM | $-48.65MM |
| Non-Operating Income | $1.20MM | $3.97MM | $3.22MM |
| R&D Expense | $27.11MM | $32.86MM | $36.85MM |
| Income(Loss) | $-38.70MM | $-41.44MM | $-45.43MM |
| Profit(Loss)* | $-38.70MM | $-41.44MM | $-45.43MM |
| Stockholders Equity | $106.34MM | $69.74MM | $82.95MM |
| Assets | $116.19MM | $81.64MM | $97.19MM |
| Operating Cash Flow | $-33.82MM | $-30.89MM | $-37.69MM |
| Capital expenditure | $0.89MM | $0.58MM | $0.08MM |
| Investing Cash Flow | $38.15MM | $36.20MM | $13.73MM |
| Financing Cash Flow | $0.07MM | $0.00MM | $53.78MM |
| Earnings Per Share** | $-0.89 | $-0.93 | $-0.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.